Zhiyuan Ke

TL;DR: Preclinical proof-of-concept that inhibiting mammalian Wnts can be achieved by targeting PORCN with small-molecule inhibitors such as C59 is offered, and that this is a safe and feasible strategy in vivo.

TL;DR: A novel potent, orally available PORCN inhibitor, ETC-1922159, that blocks the secretion and activity of all Wnts is developed that is remarkably effective in treating RSPO-translocation bearing colorectal cancer patient-derived xenografts.

TL;DR: Recombinant mouse ISM significantly suppressed mouse B16 melanoma tumour growth through inhibition of tumour angiogenesis without affecting tumour cell proliferation and binds to αvβ5 integrin on EC surface and supports EC adhesion.

TL;DR: Elevated Cat S expression in HCC was positively correlated with the presence of portal vein tumor thrombus, extra-hepatic metastasis and the degree of de-differentiation, but was not correlated with age, the existence of hepatitis B virus surface antigen and cirrhosis.

TL;DR: It is demonstrated for the first time that full‐length ADAMTS4 and its catalytically more active N‐terminal 53 kDa autocatalytic fragment both promote B16 melanoma growth and angiogenesis in mice and that the single thrombospondin‐type 1 repeat domain is essential and sufficient for the antitumorigenic activity displayed by the catalytic inactive ADAMts4 isoforms.